You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2025

AbstractFullPdf
Nov 2020162012
Dec 20202006
Jan 20214207
Feb 202152012
Mar 20218209
Apr 20214002
May 20211609
Jun 2021004
Jul 2021008
Aug 2021004
Sep 20210013
Oct 202118015
Nov 202130016
Dec 20211805
Jan 20222003
Feb 20222603
Mar 20221800
Apr 20225209
May 20223801
Jun 20222602
Jul 20221400
Aug 20222002
Sep 20222606
Oct 20222201
Nov 20221604
Dec 20221000
Jan 20231800
Feb 20231402
Mar 20231802
Apr 2023802
May 20231401
Jun 20231204
Jul 20231802
Aug 20232409
Sep 20231603
Oct 2023802
Nov 20231801
Dec 20233202
Jan 20241800
Feb 20242203
Mar 20242401
Apr 20241602
May 20242400
Jun 20242600
Jul 20248300
Aug 20241801
Sep 20241801
Oct 20245404
Nov 20244602
Dec 20241805
Jan 20253806
Feb 2025604
Mar 2025006
Apr 2025002
May 2025003
Jun 2025103
Sep 2025400
Total13840226